GlassScriptPhysician profile
John M Buonomo
NPI 1619918638
$2,193.01
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $506 · 2020: $253 · 2021: $407 · 2022: $365 · 2023: $548 · 2024: $114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $655 · Education: $6.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $654.99 |
| Education | $6.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $445.31 | 2019-2023 | Breztri, Farxiga |
| Kowa Pharmaceuticals America, INC. | $268.32 | 2019-2023 | Seglentis |
| Amarin Pharma, INC. | $241.82 | 2019-2021 | |
| Abbvie INC. | $195.54 | 2021-2024 | Vraylar, Ubrelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $164.27 | 2020-2024 | Jardiance |
| Lilly USA, LLC | $155.69 | 2019-2024 | Jardiance, Mounjaro |
| Novo Nordisk INC | $152.06 | 2020-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $87.86 | 2023-2024 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $66.43 | 2019-2022 | |
| Astellas Pharma US INC | $65.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $62.58 | 2022 | |
| Pfizer INC. | $50.67 | 2019-2024 | |
| Eisai INC. | $50.52 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $47.69 | 2023-2024 | Quviviq |
| Abbott Laboratories | $42.15 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $41.50 | 2020-2021 | |
| Eyevance Pharmaceuticals LLC | $28.75 | 2021 | |
| Circassia INC. | $26.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Buonomo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.